Lei KaChon, DiCaro Michael V, Tak Nadia, Turnbull Scott, Abdallah Ala, Cyrus Tillman, Tak Tahir
Department of Cardiovascular Medicine, Kirk Kerkorian SOM at the University of Nevada Las Vegas, Las Vegas, Nevada.
Department of Internal Medicine, Kirk Kerkorian SOM at the University of Nevada Las Vegas, Las Vegas, Nevada.
Int J Angiol. 2024 Apr 23;33(2):112-122. doi: 10.1055/s-0044-1785231. eCollection 2024 Jun.
Inferior vena cava (IVC) filters and endovascular devices are used to mitigate the risk of pulmonary embolism in patients presenting with lower extremity venous thromboembolism in whom long-term anticoagulation is not a good option. However, the efficacy and benefit of these devices remain uncertain, and controversies exist. This review focuses on the current use of IVC filters and other endovascular therapies in clinical practice. The indications, risks, and benefits are discussed based on current data. Further research and randomized controlled trials are needed to characterize the patient population that would benefit most from these interventional therapies.
下腔静脉(IVC)滤器和血管内装置用于降低下肢静脉血栓栓塞患者发生肺栓塞的风险,对于这些患者而言,长期抗凝并非理想选择。然而,这些装置的疗效和益处仍不明确,存在争议。本综述聚焦于IVC滤器和其他血管内治疗方法在临床实践中的当前应用情况。基于现有数据对其适应证、风险和益处进行了讨论。需要进一步的研究和随机对照试验来明确最能从这些介入治疗中获益的患者群体。